Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 15 IN SODIUM CHLORIDE 0 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 15 IN SODIUM CHLORIDE 0 9.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride provides potassium ions, essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Sodium chloride provides sodium ions, which are critical for electrolyte balance and osmotic pressure regulation.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion; typical maintenance dose is 10-20 mEq/hour (equivalent to approximately 200-400 mL/hour of this solution), not to exceed 40 mEq/hour or 200 mEq/day, depending on serum potassium levels and clinical status. Concentration should not exceed 40 mEq/L when administered via peripheral line; central line may be used for higher concentrations.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
The terminal elimination half-life of potassium is approximately 3-5 hours in patients with normal renal function. However, this can be clinically misleading as potassium distribution and excretion are complex; the half-life may be prolonged in renal impairment.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Primarily renal (>90% of absorbed potassium is excreted by the kidneys, with about 80-90% in urine and 10% in feces). Renal elimination follows glomerular filtration and distal tubular secretion, with minimal biliary excretion.
Category C
Category A/B
Electrolyte
Electrolyte